



2023

Financial Report

GAMIAN-Europe




GAMIAN-Europe

The voice of patients in mental health


www.gamian.eu

Operating Income



€33,696.6 accrued to 2024 for continued projects

Operating charges



Industry		
Company	Funding	Percentage of Funding
Boehringer Ingelheim International GmbH	160.550,00	30,42%
Janssens Pharmaceutica	81.840,00	15,51%
H. Lundbeck	35.000,00	6,63%
Pfizer	25.000,00	4,74%
Compass Pathfinder Ltd.	20.000,00	3,79%
Servier Affaires Medicales	16.000,00	3,03%
Angelini Pharma S.p.A	10.000,00	1,89%
Novartis Pharma AG	10.000,00	1,89%
Total Industry	358.390,00	67,91%
Non Industry		
Boston Scientific Foundation	45.000,00	8,53%
University of Munster	37.500,00	7,11%
UMCG	21.966,00	4,16%
Universiteit Maastricht	11.593,73	2,20%
Parc Sanitari Sant Joan de Déu - Cibersam	11.482,50	2,18%
Rijksuniversiteit Groningen	10.864,00	2,06%
EBC - European Brain Council	9.040,00	1,71%
Stichting Buro ENCP	7.500,00	1,42%
EPF - European Patients Forum	2.500,00	0,47%
Membership	9.875,00	1,87%
Other Donations	2.000,00	0,38%
Total Non Industry	169.321,23	32,09%
January - December 2023		
Operating income 2023	527.711,23	100%



GAMIAN-Europe
The Voice of Patients in Mental Health
www.gamian.eu
Avenue Marnix 17, 60 rue du Trône | 1000
Brussels, Belgium